Zentalis Pharmaceuticals, Inc.

Business Summary

PART I . Overview We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ...

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

Annual Reports (10-K)

Quarterly Reports (10-Q)

Recent Current Reports (8-K)

124 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

Company Identity

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API: